Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
Clinical trial NCT06059547 · COMPLETED
Trial details
- NCT number
- NCT06059547
- Sponsor
- CatalYm GmbH
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-06
- Primary completion
- 2025-10-16
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.